SLBST Pharma

SLBST Pharma is a US-based biotechnology company developing innovative therapies for endometriosis, a debilitating condition affecting millions of women.

We are focused on transforming endometriosis treatment by targeting the underlying inflammatory mechanisms driving the disease. Our lead candidate, entering Phase 2b trials, is a re-purposed version of the well-established immunomodulator hydroxychloroquine (HCQ), offering a potential first-line treatment option with a strong safety profile.

SLBST Pharma holds issued patents protecting this novel indication and is committed to delivering a cost-effective and impactful solution for patients suffering from this challenging disease. We are dedicated to advancing women’s health through targeted research and development.